--Population Science and Prevention (PSP) Program The Population Science and Prevention (PSP) Program, co-led by Pratap Kumar, Ph.D. and Gail Tomlinson, M.D., Ph.D., has 29 members, representing 4 schools and 10 departments at the Mays Cancer Center (MCC) at the University of Texas Health San Antonio (UT Health SA). The primary focus of the PSP Program is collaborative research that addresses cancer risk and prevention to develop intervention strategies. Studies are focused on our overarching goal of reducing cancer burden in our 38-county catchment area. Our emphasis has been on improving cancer screening and detection, improving access to care, and translation prevention discoveries through interventional trials. These include behavioral interventions to improve cancer outcomes, incorporating community outreach and engagement of underserved populations. PSP members have: 1) Formulated a panel of patented biomarkers for predicting recurrent risk of prostate cancer; 2) Identified epigenotypes for stratifying an endometrial cancer subtype predominantly occurring in young, obese Hispanics; and 3) Shown that exposure to aflatoxin and hepatitis C virus may cause hepatocellular carcinoma in our catchment area and other Hispanic populations. Inter- and intra-programmatic efforts have found that: 1) Yoga- based exercise and nutritional interventions can reduce circulating inflammatory cytokines, thereby enhancing survival of breast cancer patients; and 2) Texting and mobile media services help Hispanic adolescent/young adults (AYAs) quit smoking in a cost-effective manner. Through our collaborative work, we have impacted the population across our geographic area (including rural and border regions): e.g. increased identification rates of those carrying hepatitis C, and increased HPV vaccine administration, genetic risk assessment and testing, and enhanced cancer screening in genetically at-risk populations. In the upcoming Cancer Center Support Grant (CCSG) cycle, we continue to address the disproportionate burden of cancer across the age continuum ? children, AYAs, and adults ? in our catchment area. Our Program?s Specific Aims are to: 1) Discover biomarkers to enhance early detection and recurrent prediction; 2) Translate evidence-based chemotherapeutic/ nutritional/behavioral strategies to interventional trials; and 3) Enhance quality of life for cancer survivors.
These Specific Aims will be achieved by promoting intra- and inter-programmatic collaborations to translate findings into clinical interventions to benefit our population. PSP Program members hold 28 grants totaling $5.7M (direct costs), with 25% ($1.4M) from the NCI. Over the last reporting period, the PSP?s multidisciplinary investigators more than doubled their peer-reviewed publications (412 vs. 186). Of these, 21% are intra-programmatic, 14% inter-programmatic, 77% multi-institutional collaborations, and 53% with other NCI-designated Cancer Centers. In addition, 34% of PSP publications during this period were from journals with an impact factor >5. PSP members led 21 clinical research studies during 2018 and placed 171 patients on interventional studies and 332 on non-interventional studies. PSP members have used all six MCC core facilities, especially the Biostatistics and Bioinformatics Core. Initiatives are being generated by newly recruited PSP faculty whose skill sets enhance the Program scope and Specific Aims by cross-cutting translational working groups, and by close collaborations with the other MCC Programs and the UT Health SA scientific community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-25
Application #
10025095
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
25
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:
Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Sun, Xiujie; Gupta, Kshama; Wu, Bogang et al. (2018) Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. J Biol Chem 293:2841-2849
Horning, Aaron M; Wang, Yao; Lin, Che-Kuang et al. (2018) Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res 78:853-864
Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13
Gelfond, Jonathan; Goros, Martin; Hernandez, Brian et al. (2018) A System for an Accountable Data Analysis Process in R. R J 10:6-21

Showing the most recent 10 out of 989 publications